PMID- 29518524 OWN - NLM STAT- MEDLINE DCOM- 20190130 LR - 20190130 IS - 1569-1802 (Electronic) IS - 0945-053X (Linking) VI - 68-69 DP - 2018 Aug TI - The impaired proteases and anti-proteases balance in Idiopathic Pulmonary Fibrosis. PG - 382-403 LID - S0945-053X(17)30471-7 [pii] LID - 10.1016/j.matbio.2018.03.001 [doi] AB - Idiopathic Pulmonary Fibrosis (IPF) is a devastating chronic, progressive and irreversible disease that remains refractory to current therapies. Matrix metalloproteinases (MMPs) and their inhibitors, tissue inhibitors of MMPs (TIMPs), have been implicated in the development of pulmonary fibrosis since decades. Coagulation signalling deregulation, which influences several key inflammatory and fibro-proliferative responses, is also essential in IPF pathogenesis, and a growing body of evidence indicates that Protease-Activated Receptors (PARs) inhibition in IPF may be promising for future evaluation. Therefore, proteases and anti-proteases aroused great biomedical interest over the past years, owing to the identification of their potential roles in lung fibrosis. During these last decades, numerous other proteases and anti-proteases have been studied in lung fibrosis, such as matriptase, Human airway trypsin-like protease (HAT), Hepatocyte growth factor activator (HGFA)/HGFA activator inhibitor (HAI) system, Plasminogen activator inhibitor (PAI)-1, Protease nexine (PN)-1, cathepsins, calpains, and cystatin C. Herein, we provide a general overview of the proteases and anti-proteases unbalance during lung fibrogenesis and explore potential therapeutics for IPF. CI - Copyright (c) 2018. Published by Elsevier B.V. FAU - Menou, Awen AU - Menou A AD - Institut National de la Sante Et de la Recherche Medicale, U1152 Paris, France; Departement Hospitalo, Universitaire FIRE, Paris, France; Laboratoire d'Excellence Inflamex, Paris, France; Universite Paris Diderot - Paris 7, Sorbonne Paris Cite, Paris, France. FAU - Duitman, JanWillem AU - Duitman J AD - Institut National de la Sante Et de la Recherche Medicale, U1152 Paris, France; Departement Hospitalo, Universitaire FIRE, Paris, France; Laboratoire d'Excellence Inflamex, Paris, France; Universite Paris Diderot - Paris 7, Sorbonne Paris Cite, Paris, France. FAU - Crestani, Bruno AU - Crestani B AD - Institut National de la Sante Et de la Recherche Medicale, U1152 Paris, France; Departement Hospitalo, Universitaire FIRE, Paris, France; Laboratoire d'Excellence Inflamex, Paris, France; Universite Paris Diderot - Paris 7, Sorbonne Paris Cite, Paris, France; Assistance Publique-Hopitaux de Paris, Hopital Bichat, Service de Pneumologie A, Paris, France. Electronic address: bruno.crestani@aphp.fr. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20180306 PL - Netherlands TA - Matrix Biol JT - Matrix biology : journal of the International Society for Matrix Biology JID - 9432592 RN - 0 (Proteinase Inhibitory Proteins, Secretory) RN - 0 (Tissue Inhibitor of Metalloproteinases) RN - EC 3.4.- (Peptide Hydrolases) RN - EC 3.4.24.- (Matrix Metalloproteinases) SB - IM MH - Gene Expression Regulation MH - Humans MH - Idiopathic Pulmonary Fibrosis/*metabolism MH - Matrix Metalloproteinases/metabolism MH - Peptide Hydrolases/*metabolism MH - Proteinase Inhibitory Proteins, Secretory/*metabolism MH - Signal Transduction MH - Tissue Inhibitor of Metalloproteinases/metabolism OTO - NOTNLM OT - Anti-protease OT - Cysteine protease OT - Idiopathic Pulmonary Fibrosis OT - Matrix metalloproteinase OT - Serine protease EDAT- 2018/03/09 06:00 MHDA- 2019/01/31 06:00 CRDT- 2018/03/09 06:00 PHST- 2017/12/15 00:00 [received] PHST- 2018/02/28 00:00 [revised] PHST- 2018/03/01 00:00 [accepted] PHST- 2018/03/09 06:00 [pubmed] PHST- 2019/01/31 06:00 [medline] PHST- 2018/03/09 06:00 [entrez] AID - S0945-053X(17)30471-7 [pii] AID - 10.1016/j.matbio.2018.03.001 [doi] PST - ppublish SO - Matrix Biol. 2018 Aug;68-69:382-403. doi: 10.1016/j.matbio.2018.03.001. Epub 2018 Mar 6.